Norway· NO-ID_770ED70A-5FB7-497D-9BF6-DCB5C36F55A3
Lamprene
A clofazimine product containing clofazimine, registered in Norway by Novartis. The same ATC class is registered in 7 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Clofazimine is registered in 7 of 19 countries.
Countries holding a registration under ATC J04BA01 (clofazimine), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 5 of them publish a price we can compare per daily dose
Clofazimine · ATC J04BA01
7 / 19 countries
- Czechiaprice
- Franceprice
- Japan
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Clofazimine
- Manufacturer
- Novartis
- Country
- Norway (NO)
- ATC code
- J04BA01
- ATC class
- Clofazimine
- Defined daily dose
- 0.1 g, O
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
- no_merkevare_idID_770ED70A-5FB7-497D-9BF6-DCB5C36F55A3
- no_varenummer206836100
- gtin18901109360035
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
158 interactions on record for clofazimine.
Graded by severity as the source publishes them — 37 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Clofazimine · interactions on record
158 records
- 37 severe
- 119 moderate
- 2 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- PapaverinC04AX38severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Clofazimine in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesLampreneNovartis Pharmaceuticals Corporation
- CzechiaLAMPRENE
- FranceLAMPRENE 50 mg, capsule molleNOVARTIS PHARMA
- United KingdomClofazimine 100mg capsulesSpecial Order
- SpainLAMPREN CAPSULASNovartis Farmaceutica S.A.
Authorised across Europe · EMA
The same active substance is authorised in 1 EEA country. Names it is sold under:
- France · Lamprene
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/62f1a7fc-afc6-4bb3-8e08-7d0d5368a443 GET /v1/drugs/62f1a7fc-afc6-4bb3-8e08-7d0d5368a443?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Kapsel, myk",
"source": "fest",
"status": "A",
"atc_name": "Klofazimin",
"merkevare_id": "ID_770ED70A-5FB7-497D-9BF6-DCB5C36F55A3",
"name_form_strength": "Lamprene kaps 50 mg",
"prescription_group": "C"
}See everything about clofazimine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.